NCT00487227

Brief Summary

It is often assumed that levels of caffeine found in 'decaffeinated' beverages are below any psychopharmacological threshold. However, recent findings indicate that caffeine doses as low as 9 mg may be psychoactive. The effects of caffeine have also been shown up to 6 hours post-administration. The study aimed to establish the lowest active dose of caffeine, and to ascertain the duration of any effects.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at P25-P50 for not_applicable healthy

Timeline
Completed

Started Jun 2005

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2005

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2005

Completed
1.6 years until next milestone

First Submitted

Initial submission to the registry

June 15, 2007

Completed
3 days until next milestone

First Posted

Study publicly available on registry

June 18, 2007

Completed
Last Updated

October 8, 2015

Status Verified

October 1, 2015

First QC Date

June 15, 2007

Last Update Submit

October 6, 2015

Conditions

Healthy

Keywords

caffeinecoffeedecaffeinatedcognitionmoodautonomic

Outcome Measures

Primary Outcomes (4)

  • Change from baseline speed of attention

    1 hour

  • Change from baseline speed of attention

    3 hours

  • Change from baseline speed of attention

    6 hours

  • Change from baseline speed of attention

    9 hours

Secondary Outcomes (24)

  • Change from baseline accuracy of attention

    1 hour

  • Change from baseline accuracy of attention

    3 hours

  • Change from baseline accuracy of attention

    6 hours

  • Change from baseline accuracy of attention

    9 hours

  • Change from baseline speed of memory

    1 hour

  • +19 more secondary outcomes

Study Arms (4)

Placebo

PLACEBO COMPARATOR
Drug: Placebo

2.5mg caffeine

EXPERIMENTAL
Drug: caffeine

5mg caffeine

EXPERIMENTAL
Drug: caffeine

10mg caffeine

EXPERIMENTAL
Drug: caffeine

Interventions

caffeineDRUG
10mg caffeine2.5mg caffeine5mg caffeine
PlaceboDRUG
Placebo

Eligibility Criteria

Age18 Years - 35 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • native English speaker

You may not qualify if:

  • pregnancy
  • medication
  • anaemia
  • heart disorder
  • diabetes
  • respiratory disorder
  • epilepsy
  • asthma
  • panic attacks
  • habitual smoking
  • food allergy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Interventions

Caffeine

Intervention Hierarchy (Ancestors)

XanthinesAlkaloidsHeterocyclic CompoundsPurinonesPurinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-Ring

Study Officials

  • Andrew Scholey

    Northumbria University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Sponsor Type
OTHER

Study Record Dates

First Submitted

June 15, 2007

First Posted

June 18, 2007

Study Start

June 1, 2005

Study Completion

November 1, 2005

Last Updated

October 8, 2015

Record last verified: 2015-10